Brief: Landmark Bio to Manufacture Galapagos' Oncology CAR-T Cell Therapy Clinical Programs at the Point-of-Care

Lakefront Biotherapeutics NV

06/11/2023 12:46

Nov 6 (Reuters) - Galapagos NV  GLPG.AS :
    * LANDMARK BIO SIGNS MULTI-YEAR AGREEMENT TO MANUFACTURE
GALAPAGOS' ONCOLOGY CAR-T CELL THERAPY CLINICAL PROGRAMS AT THE
POINT-OF-CARE
    * LANDMARK BIO- FINANCIAL TERMS OF AGREEMENT WERE NOT
DISCLOSED

Source text for Eikon:  ID:nPnbF0PW5a 
Further company coverage:  GLPG.AS 

 ((Reuters.Briefs@thomsonreuters.com;))